A Phase 3, Open-label, Multicenter, Randomized Trial of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy as First-line Maintenance Therapy in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01/ENGOT-ov89/GEICO144- O/GOG-3112)
Ovarian Cancer
Kuala Lumpur Hospital (HKL)
PRINCIPAL INVESTIGATOR
NOOR ZAFIFAH BINTI ZAKARIA
CONTACT
SC: Nur Fadhilah Megat Ismail
National Cancer Institute (IKN)
PRINCIPAL INVESTIGATOR
WONG YOKE FUI, Florence
CONTACT
SC: Sarah Khairul Annuar
Sarawak General Hospital
PRINCIPAL INVESTIGATOR
YUSRA BINTI HADI
CONTACT
SC: Nor Atikah Hamdi
Sultan Ismail Hospital, Johor Bahru
PRINCIPAL INVESTIGATOR
KUMUTHA A/P CHALAYA
CONTACT
SC: Narmatha Gurumoorthy
Retrospective Analysis of Real-World Treatment Patterns and Clinical Outcomes in Patients with Locally Advanced Cervical Cancer (LACC) in an Ethnically Diverse Population
Locally Advanced Cervical Cancer (LACC)
Kuala Lumpur Hospital (HKL)
PRINCIPAL INVESTIGATOR
PRATHEPAMALAR A/P YEHGAMBARAM
CONTACT
SC: Irdina Fakhira Mohd Fadzir
National Cancer Institute (IKN)
PRINCIPAL INVESTIGATOR
WONG YOKE FUI, Florence
CONTACT
SC: Yong Xian Lerk
Phase II single arm, open label study of artesunate for the treatment of human papilloma virus positive high grade cervical intraepithelial neoplasia (CIN2/3)
High grade cervical intraepithelial neoplasia
National Cancer Institute (IKN)
PRINCIPAL INVESTIGATOR
Jamil Bin Omar
CONTACT
SC: Hidayati Binti Mohd Sha’ari
Sarawak General Hospital
PRINCIPAL INVESTIGATOR
KERVINDRAN A/L MOHANASUNDARAM
CONTACT
SC: Azian Nadiah Faisal
Selayang Hospital
PRINCIPAL INVESTIGATOR
VICKNESH A/L VISVALINGAM
CONTACT
Nor Azizah Mohamad Nazri
Ampang Hospital
PRINCIPAL INVESTIGATOR
YONG CHEE MENG
CONTACT
SC: Nur Syakirah Mohamed Elias